BioCardia, Inc. — fact timeline

BioCardia, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“June 9, 2026, received written notice that, based on review of the compliance plan, the Nasdaq staff granted the Company an extension to October 7, 2026 to regain compliance with the Rule. The Company is filing this Current Report on Form 8-K (this “Report”) to provide an update to its compliance with continued listing requirements as set forth in Nasdaq Listing Rule 5550(b)(1). On June 8, 2026, the Company filed an 8-K and issued a press release announcing that the Company sold 3,509,604 shares at an average price of $1.279 on Friday, June 5, 2026. The shares were sold pursuant to the Company”

BioCardia, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 10, 2026, BioCardia, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based on the Company’s stockholders’ equity of $895,000 as of December 31, 2025, it is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The Company has until May 25, 2026 to provide Nasdaq with a plan to regain compliance with the foregoing listing requirement. If the Company’s plan to regain compliance is acc”

BioCardia, Inc. reported financial results for the year ended December 31, 2025.

“On March 24, 2026, BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2025.”

BioCardia, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“April 1, 2025, BioCardia, Inc. (the “Company,” “we,” “us” and “our”) received a notification letter (the “Notice”) from the Nasdaq Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its amount of stockholders’ equity had fallen below the $2,500,000 required minimum for continued listing set forth in Nasdaq Listing Rule 5550(b)(1). As noted in the Original 8-K, the Company had until May 16, 2025 to provide Nasdaq with a specific plan to achieve and sustain compliance. The Company submitted its plan to regain compliance on May 15, 2025”

BioCardia, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5550(b)(1)).

“December 31, 2024, it is no longer in compliance with the minimum stockholders’ equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(1). The Company has until May 16, 2025 to provide Nasdaq with a plan to regain compliance with the foregoing listing requirement. If the Company’s plan to regain compliance is accepted, Nasdaq may grant an extension of up to 180 calendar days from April 1, 2025 for the Company to evidence compliance. The Notice has no immediate effect on the listing or trading of the Company’s common stock and the”

BioCardia, Inc. reported first quarter of 2024 results: revenue approximately $55,000.

“Revenues were approximately $55,000 for the three months ended March 2024, compared to approximately $64,000 for the three months ended March 2023.”

BioCardia, Inc. reported financial results for the year ended December 31, 2023.

“On March 27, 2024, BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2023.”

BioCardia, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an initial period of 180 calendar days, or until March 11, 2024 (the “Minimum Bid Price Compliance Date”), to regain compliance with”

BioCardia, Inc. received a nasdaq hearing update notice regarding market value (rules 5550(b)(2)).

“March 12, 2024. Additionally, as previously disclosed on a Current Report on Form 8-K filed with the SEC on September 15, 2023, on September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an”

BioCardia, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“on September 13, 2023, the Company received a separate written notice (the “Minimum Bid-Price Notice”) from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Minimum Bid-Price Notice provided that, in accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company would have an initial period of 180 calendar days, or until March 11, 2024 (the “Minimum Bid Price Compliance Date”), to regain compliance w”

BioCardia, Inc. shareholders approved Frequency of future stockholder advisory votes on the compensation of its named executive officers at the 2023-10-18 meeting.

“The Company will hold future say on pay votes on an annual basis, as was recommended by the Company’s Board of Directors in the Company’s proxy statement for the 2023 annual meeting of stockholders held on October 18, 2023 (the "2023 Annual Meeting") and was subsequently approved by the Company’s stockholders at the 2023 Annual Meeting”

BioCardia, Inc. reported financial results for the quarter ended September 30, 2023.

“On November 8, 2023, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.”

BioCardia, Inc. shareholders approved Resolution Indicating how Frequently to Hold an Advisory Vote on Executive Compensation at the 2023-10-18 meeting.

“Proposal 4 – Resolution Indicating how Frequently to Hold an Advisory Vote on Executive Compensation . A frequency of every one year for an advisory vote on executive compensation was approved. 1 YEAR 2 YEARS 3 YEARS Abstentions Broker Non-votes 6,031,521 23,503 502,667 100,632 7,127,248”

BioCardia, Inc. shareholders approved Approval, on an Advisory Basis, of the Company’s Executive Compensation at the 2023-10-18 meeting.

“Proposal 3 – Approval, on an Advisory Basis, of the Company ’ s Executive Compensation . The Company’s executive compensation was approved on an advisory basis. Votes For Votes Against Abstentions Broker Non-votes 4,375,841 2,264,503 17,979 7,127,248”

BioCardia, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2023-10-18 meeting.

“Proposal 2 – Ratification of the Appointment of Independent Registered Public Accounting Firm. The appointment of PKF San Diego, LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2023 was ratified. Votes For Votes Against Abstentions Broker Non-votes 13,062,509 695,047 28,015”

BioCardia, Inc. shareholders approved Election of Class I directors at the 2023-10-18 meeting.

“Proposal 1 – Election of Directors . The following nominees were elected as Class I directors to serve until the 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified: Nominee Votes For Withheld Broker Non-votes Peter Altman, Ph.D. 4,390,666 2,267,657 7,127,248 Bill Facteau 4,500,019 2,158,304 7,127,248”

BioCardia, Inc. reported financial results for second quarter of 2023.

“today reports financial results for the second quarter of 2023”

BioCardia, Inc. terminated Purchase Agreement with Lincoln Park Capital Fund, LLC (effective 2023-06-30).

“On June 30, 2023, BioCardia, Inc. (the “Company”), provided notice to Lincoln Park Capital Fund, LLC of its election to terminate the Purchase Agreement between them dated March 29, 2021 (the “Purchase Agreement”).”

BioCardia, Inc. reported first quarter of 2023 results: revenue approximately $64 thousand.

“CellProthera’s next clinical study, and potential early access commercialization, which could begin in 2024. First Quarter 2023 Financial Results: > Revenues were approximately $64 thousand for the three months ended March 2023, compared for approximately $60 thousand in the three months ended March 2022. > Research and development expenses increased to a”

BioCardia, Inc.: Amended and restated bylaws to update advance notice procedures for director nominations and stockholder business proposals, align with SEC rules and Delaware law, and include technical changes (effective 2023-04-30).

“On April 30, 2023, the board of directors (the “Board”) of BioCardia, Inc. (the “Company”), acting upon the recommendation of the Board’s Nominating and Corporate Governance Committee, approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became effective immediately.”

BioCardia, Inc. reported financial results for the year ended December 31, 2022.

“BioCardia, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.”

BioCardia, Inc. reported financial results for the quarter ended September 30, 2022.

“On November 9, 2022, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.”